GBX Summits ™ works in conjunction with some of the world's most prominent leaders and visionaries across a variety of key industries in order to produce cutting edge programmes that simulate, educate and accelerate innovation.
Steering Committee And Speaker Faculty At A Glance
Dr. Gottschalk is Group Vice President, Purification Technologies, with a global responsibility for bioseparation products at Sartorius Stedim Biotech. He worked in different capacities for Bayer Health Care from 1991-2004 and became head of the GMP protein purification facility in Wuppertal.
Prof. Dr. Thomas Herget is currently Head of Processing Technologies within the Merck Millipore process solutions division of Merck KGaA, where he develops new methods and materials for bioprocessing. He is also a medical professor at the University of Mainz and a biochemistry professor at the TU Darmstadt. He has received several awards, submitted 25 patents and authored more than 50 peer-reviewed papers. From 2004-2010, Prof. Dr. Thomas Herget served as the Director, New Technology Evaluation within Merck KGaA’s Chemicals R&D division. In that role, he ran laboratories in Darmstadt (Germany) and oversaw the R&D activities of Novagen (Madison) and Calbiochem (San Diego). In 2000, he joined the Munich-based Axxima Pharmaceuticals AG (now GPC Biotech), a biotech startup founded by Prof. Axel Ullrich, to focus on the development of protein kinase inhibitors in infectious diseases.
Eric de La Fortelle is Global Head, External Research and Technologies, for Roche Partnering in Basel, Switzerland. He heads a group with a global mandate to find partners, establish contracts and manage alliances with companies offering innovative technologies for every stage of product discovery, development and lifecycle. Such technologies include discovery technologies (assays, small molecules, biologics, RNA, cell therapies) as well as bioinformatics, biomarkers, safety, and formulation/delivery technologies. Eric is a scientist by training, with contributions in the field of structure-based drug design (determination of 3D structures of protein targets by X-ray crystallography).
Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam. In 2003, he was one of the founders of Bioceros BV were he currently hold a position of CSO.
Bioceros generates production cell lines for the industry and used its proprietary CHOBC® platform to generate a portfolio of cell lines producing biosimilar monoclonal antibodies. Since the acquisition of Bioceros by EPIRUS in 2015, he extended this expertise and developed a complete process toolbox to fit biosimilar CQAs. After the acquisition of Epirus NL by the Polpharma Biologics group in June 2016, he has continued to work on biosimilar development and developed the SPOT™ technology to improve cell line productivity. Next to biosimilars, Dr. Boon is also responsible for the discovery and development of innovative new molecular antibody entities, which now within the Polpharma Biologics group can be extended to GMP production and clinical testing. In addition, before he founded Bioceros, he held positions as CSO for MacroZyme BV, 4AZA Bioscience NV, FF Pharma and VP Preclinical for PanGenetics BV and Tanox. Dr. Boon is author of over 260 papers in international scientific journals in the field of medical biotechnology.
Dr. Rod MacKenzie, Ph.D serves as Senior Vice President and Head of Worldwide Research for PharmaTherapeutics R&D at Pfizer Inc. and has been its Groton site leader since April 25, 2012 and has been the President of PharmaTherapeutics Research & Development since May 2010.
Ted Torphy, PhD, has 30 years’ experience and a successful record in both small-molecule and large-molecule drug discovery. In addition, Dr. Torphy is a recognized leader in bringing open innovation to the pharmaceutical industry.